FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 253 filers reported holding FATE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.84 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $1,460,000 | +11.8% | 65,144 | +23.1% | 0.00% | 0.0% |
| Q2 2022 | $1,306,000 | +270.0% | 52,903 | +793.3% | 0.00% | +200.0% |
| Q3 2021 | $353,000 | -40.0% | 5,922 | -12.7% | 0.00% | 0.0% |
| Q2 2021 | $588,000 | -64.5% | 6,782 | -64.4% | 0.00% | -75.0% |
| Q1 2021 | $1,658,000 | -0.8% | 19,033 | +3.4% | 0.00% | 0.0% |
| Q4 2020 | $1,671,000 | +103.0% | 18,403 | -10.9% | 0.00% | +100.0% |
| Q3 2020 | $823,000 | +48.8% | 20,645 | +28.0% | 0.00% | 0.0% |
| Q2 2020 | $553,000 | +2.8% | 16,123 | -33.4% | 0.00% | 0.0% |
| Q1 2020 | $538,000 | +657.7% | 24,206 | +455.2% | 0.00% | – |
| Q4 2018 | $71,000 | 0.0% | 4,360 | 0.0% | 0.00% | – |
| Q3 2018 | $71,000 | +44.9% | 4,360 | 0.0% | 0.00% | – |
| Q2 2018 | $49,000 | – | 4,360 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $34,095 | 9.92% |
| Redmile Group, LLC | 12,957,222 | $130,738,370 | 5.35% |
| GCM Grosvenor Holdings, LLC | 1,037,256 | $10,465,913 | 2.67% |
| Casdin Capital, LLC | 2,050,000 | $20,684,500 | 1.60% |
| DAFNA Capital Management LLC | 550,940 | $5,558,985 | 1.57% |
| Artal Group S.A. | 2,600,000 | $26,234 | 1.46% |
| Monaco Asset Management SAM | 250,000 | $2,522,500 | 0.76% |
| Parametrica Management Ltd | 32,254 | $325,443 | 0.67% |
| Boxer Capital, LLC | 1,250,000 | $12,612,500 | 0.66% |
| Bellevue Group AG | 4,861,279 | $49,050,305 | 0.65% |